Reference is made to the prospectus (the "Prospectus") dated 30 September 2016 concerning, inter alia, the subsequent offering (the "Subsequent Offering") of minimum 1 and maximum 13,333,334 new shares (the "Offer Shares") in Hofseth BioCare ASA ("HBC" or the "Company", ticker "HBC") and the stock exchange notice published on 17 October 2016 regarding allocation of Offer Shares in the Subsequent Offering.

The share capital increase related to the Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises. The share capital has been increased with NOK 1,027,494 through issuance of 1,027,494 new shares.

The new share capital is thus NOK 233,499,759 divided by 233,499,759 shares, each with a par value of NOK 1.

The new shares will be listed and become tradable on Oslo Axess upon duly registration in the VPS-register on 27 October 2016.

For further information, please contact:
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.